Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term experience with pentosanpolysulfate in interstitial cystitis

J V Jepsen1, M Sall, P R Rhodes

  • 1Department of Surgery, University of Wisconsin, Madison Hospital and Clinics, USA.

Urology
|March 24, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.

The American journal of pathology·1995
Same author

[Placental site trophoblastic tumor. Morphology, differential diagnosis and prognosis].

Der Pathologe·1995
Same author

Retinal vascular hamartoma in von Hippel-Lindau disease.

Archives of ophthalmology (Chicago, Ill. : 1960)·1995
Same author

Dosimetry of iodine-123-epidepride: a dopamine D2 receptor ligand.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·1995
Same author

The use of CD31 and collagen IV as vascular markers. A study of 56 vascular lesions.

Pathology, research and practice·1995
Same author

[Fatigue fractures of the sacrum in primary biliary liver cirrhosis].

Aktuelle Radiologie·1995

Long-term use of pentosanpolysulfate sodium (PPS) benefits a subset of interstitial cystitis (IC) patients. Less constant pain at baseline may predict a positive response to this oral therapy.

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Pentosanpolysulfate sodium (PPS) is an oral medication approved for interstitial cystitis (IC).
  • Previous studies showed symptom improvement in 28-63% of patients, but lacked long-term data.
  • No specific patient characteristics, aside from Hunner's ulcer, were previously identified as predictors of PPS response.

Purpose of the Study:

  • To evaluate the long-term efficacy of oral PPS in interstitial cystitis (IC) patients.
  • To identify baseline characteristics that predict long-term response to PPS therapy.

Main Methods:

  • Analysis of baseline and follow-up data from 97 IC patients in a compassionate use study (1987-1995).
  • Patients were monitored every 3 months; follow-up included questionnaires and lab tests.
  • An updated questionnaire was sent to patients who discontinued treatment.

Related Experiment Videos

Main Results:

  • 11.3% of patients continued PPS by study end, with 6.2% on continuous therapy for over 18 months.
  • 3% achieved long-term remission after discontinuing PPS, with an additional 15% experiencing substantial remission periods.
  • A weak correlation was found between less constant pain and PPS treatment duration (P=0.0439); no other baseline predictors were identified.

Conclusions:

  • Long-term benefit from oral PPS in interstitial cystitis (IC) ranges from 6.2% to 18.7% of patients.
  • Less constant pain emerged as the sole baseline predictor of a positive response to PPS.